Dapagliflozin in Patients with Chronic Kidney DiseaseHiddo J.L. Heerspink, David C. Wheeler, Peter Rossing et al.|New England Journal of Medicine|2020Cited by 5.2k
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policyAdeera Levin, Chih-Wei Yang, Robert G. Nelson et al.|The Lancet|2017Cited by 923
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trialHiddo J.L. Heerspink, Rey Isidto, Bergur V. Stefánsson et al.|Nephrology Dialysis Transplantation|2019Cited by 216
The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristicsDavid C. Wheeler, Hiddo J.L. Heerspink, Bergur V. Stefánsson et al.|Nephrology Dialysis Transplantation|2020Cited by 189